Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2015 Dec;8(4):339-43.
doi: 10.1007/s12178-015-9310-y.

Rank ligand as a target in musculoskeletal neoplasms

Gregory M Cote  1
Affiliations

Rank ligand as a target in musculoskeletal neoplasms

Gregory M Cote. Curr Rev Musculoskelet Med. 2015 Dec.

Abstract

Receptor activator of nuclear factor-κB ligand (RANKL) is a tumor necrosis factor (TNF) family member, which signals through the osteoclast surface RANK. As such, RANKL is required for osteoclast differentiation and function, namely bone resorption. There is now growing evidence that RANKL is a therapeutic target for musculoskeletal neoplasms, namely giant cell tumor of bone (GCTB) and osteosarcoma.

Keywords: Giant cell tumor of bone; Osteosarcoma; RANK; RANKL.

PubMed Disclaimer

Figures

Fig. 1
Fig. 1
Shown are axial and coronal MRI images of a GCTB of the wrist in a patient treated with denosumab for 3 months
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

References

    1. Jo VY, Fletcher CD. WHO classification of soft tissue tumours: an update based on the 2013 (4th) edition. Pathology; 46:95–104. - PubMed
    1. Takahashi N, Udagawa N, Suda T. A new member of tumor necrosis factor ligand family, ODF/OPGL/TRANCE/RANKL, regulates osteoclast differentiation and function. Biochem Biophys Res Commun. 1999;256:449–55. doi: 10.1006/bbrc.1999.0252. - DOI - PubMed
    1. Cox TR, Rumney RM, Schoof EM, Perryman L, Hoye AM, Agrawal A, et al. The hypoxic cancer secretome induces pre-metastatic bone lesions through lysyl oxidase. Nature; 522:106–10. - PMC - PubMed
    1. Bekker PJ, Holloway DL, Rasmussen AS, Murphy R, Martin SW, Leese PT, et al. A single-dose placebo-controlled study of AMG 162, a fully human monoclonal antibody to RANKL, in postmenopausal women. J Bone Miner Res. 2004;19:1059–66. doi: 10.1359/JBMR.040305. - DOI - PubMed
    1. Bone HG, Chapurlat R, Brandi ML, Brown JP, Czerwinski E, Krieg MA, et al. The effect of three or six years of denosumab exposure in women with postmenopausal osteoporosis: results from the FREEDOM extension. J Clin Endocrinol Metab; 98:4483–92. - PMC - PubMed

LinkOut - more resources